Primary myelofibrosis 

Should I even worry about Intermediate PMF if I have stage IIIa CRLM?🤔

At 22:40, I wrongly described that grape juice is a strong CYP3A4 inhibitor. It is grapefruit juice, not grape juice.

This is so helpful -- thank you!

New drug approval: Momelotinib On September 15, 2023, the FDA approved momelotinib for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary or secondary myelofibrosis, and disease-related anemia.Findings from the phase 3 MOMENTUM trial (NCT04173494), as well as data from a subpopulation of adult patients with anemia from the phase 3 SIMPLIFY-1 trial (NCT01969838), supported the regulatory decision. Twenty-five percent of patients with symptomatic and anemic myelofibrosis who were previously exposed to a JAK inhibitor experienced at least a 50% reduction in tumor symptom score (TSS) with momelotinib vs 9% of patients treated with danazol, which translated to a treatment difference of 16% (95% CI, 6%-26%; P < .01). Additionally, 30% of patients in the momelotinib arm achieved transfusion independence (TI) vs 20% of those in the danazol arm, which translated to a noninferiority treatment difference of 14% (95% CI, 2%-25%; P = .023). Spleen volume reduction and a decrease in anemia-related symptoms were also observed with momelotinib.

What is the probability that anisocytosis, poikilocytosis and teardrop cells in the blood is myelofibrosis

New 5th edition of WHO classification was published. No major changes in PMF. www.nature.com/articles/s41375-022-01613-1#Tab8